Recent advancements have been made in the systemic treatment of patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers (ABCs) allowing for numerous effective treatment lines [3,4]. This evidence concerns the gene ERBB2 and breast carcinoma.